Phase III Trials Begin for Boehringer's Hepatitis C Drug
Boehringer begins late-stage hep C trial
Boehringer Ingelheim has begun enrolling patients in North America for a phase III trial of its chronic hepatitis C virus (HCV) candidate, which already has fast track designation from US regulators.
BI 201335 is an oral protease inhibitor and will be tested with standard-of-care in both treatment-naive and treatment -experienced patients with chronic genotype-1 HCV.
Continue reading this entire article: